Aerosol Biology Small Animal Models

气溶胶生物学小动物模型

• 批准号: 7641634
• 负责人: Robert MARK Buller
• 金额: $ 33.87万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-03-01 至 2009-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7641634
• 关键词: Acclimatization; Aerosols; Air; Animal Husbandry; Animal Model; Animals; Bacteria; Basic Science; Biology; Biomedical Research; Biotechnology; Categories; Cells; Clinical Services; Custom; Detection; Disease; Early Intervention; End Point; Generations; Health; Human; Infection; Intervention; Laboratories; Literature; Medical Surveillance; Methods; Modeling; Molecular; Mus; National Institute of Allergy and Infectious Disease; Operative Surgical Procedures; Oryctolagus cuniculus; Particle Size; Pathogenesis; Pathology; Pneumonic Plague; Preclinical Testing; Qualifying; Quarantine; Range; Rattus; Reporting; Research; Research Personnel; Respiratory System; Respiratory Tract Infections; Route; Sampling; Services; Smallpox; Specimen; Techniques; Testing; Therapeutic; Tissues; Virus; Writing; aerosolized; biosafety level 3 facility; design; in vivo; instrumentation; pathogen; prophylactic; respiratory; response; sample collection

The Aerosol Biology/Small Animal Models Core, hereafter referred to as the ABSAM Core or Core, will provide support for smallpox and pneumonic plague research as these diseases will be the most intensely studied NIAID Category A agents in Region 7. Other in vivo pathogen models wil be developed with the judicious selection of consultants, and as the needs arise Although the Core will be capable of infecting animals through a full range of inoculation routes, it will provide exceptional support for the use of respiratory routes of infection. The respiratory tract is the route of infection of the majority of human pathogens and will likely be the target of bioweapons; however, there _s a paucity of information in the scientific literature describing the molecular pathogenesis of NIAID category A, B, and C agents following respiratory tract infections, and the innate and mucosal responses to such infections. The starting point for the study of interactions of pathogens with the respiratory tract is a reproducible and efficient method for mimicking the natural infection. The Core will have expertise to infect animals by the intranasal, intratracheal, and aerosol exposure routes of inoculation. A major focus of the Core will be to provide support for the generation and quantification of aerosols with a wide range of mean aerodynamic particle sizes permitting the delivery of both bacteria and viruses to distinct regions of the respiratory tract. Existing and custom designed instrumentation will be used to support the study of basic questions in pathogenesis following aerosol infection, and to develop specific challenge models for preclinical testing of therapeutics and prophylactics for NIAID category A, B. and C agents. The Core will have the capacity to aerosolize and deliver therapeutics to the respiratory tract for the study of early intervention strategies, and wilt develop and test instrumentation designed to inactivate bioparticles in the air. Additional Core services will include: animal acquisition, quarantine and acclimation, health surveillance, husbandry, specimen collection, surgical services, clinical laboratory sample analysis, pathology services, and report writing. The Core will support studies in Region 7, at other Centers in the RCE network, and those originating from qualified biotechnology companies. Small biotechnology companies may find this Core particularly attractive as they will likely lack BSL-3 facilities, and the required regulatory oversight for using animals in biomedical research (AAALAC, USDA, and PHS). In addition, these companies will typically lack the expertise to carry out in vivo infections, to provide animal husbandry for infected animals, and to perform techniques necessary to acquire specimens for determination of experimental end-points.

气溶胶生物学/小动物模型核心（以下称为ABSAM核心或核心）将提供支持 对于天花和肺鼠疫研究，这些疾病将是最深入研究的NIAID类别 区域7中的代理商。其他体内病原体模型将与明智的顾问选择一起开发 尽管核心将能够通过各种接种路线感染动物，但它会出现需求 为使用呼吸道感染途径提供出色的支持。呼吸道是感染的途径 大多数人类病原体，可能是生物武器的靶标；但是，_信息很少 在描述NIAID类别A，B和C代理的分子发病机理的科学文献中 呼吸道感染以及对此类感染的先天和粘膜反应。 研究病原体与呼吸道相互作用的起点是可重复有效的 模仿自然感染的方法。核心将具有专业知识来感染鼻内的动物， 气管内和气溶胶暴露途径接种途径。核心的主要重点是为 具有广泛平均空气动力学粒径的气溶胶的生成和定量允许输送 细菌和病毒均与呼吸道不同区域的病毒。现有和定制设计的仪器 将用于支持气溶胶感染后发病机理中基本问题的研究，并开发特定 NIAID类别A，B和C代理的临床前测试临床前测试的挑战模型。这 核心将有能力为呼吸道燃气和输送治疗剂，以进行早期研究 干预策略以及枯萎的仪器开发和测试旨在使空气中的生物颗粒灭活的仪器。 其他核心服务将包括：动物获取，隔离和适应，健康监视，饲养， 标本收集，外科服务，临床实验室样本分析，病理学服务和报告写作。 核心将支持RCE网络中其他中心的第7区研究，以及源自合格的研究 生物技术公司。小型生物技术公司可能会发现这种核心特别有吸引力，因为 缺乏BSL-3设施，以及在生物医学研究中使用动物所需的监管监督（AAALAC，USDA， 和PHS）。此外，这些公司通常会缺乏进行体内感染的专业知识，以提供动物 为受感染动物的饲养，并执行获得标本所需的技术以确定 实验终点。